Watchlist Price Alert

Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · Real-Time Price · USD

13.61

-0.35 (-2.51%)

At close: May 15, 2025, 10:45 AM

-2.51% (1D)

Bid	13.56
Market Cap	1.98B
Revenue (ttm)	n/a
Net Income (ttm)	-453.94M
EPS (ttm)	-2.67
PE Ratio (ttm)	-5.1
Forward PE	-5.55
Analyst	Buy

Ask	13.62
Volume	71,228
Avg. Volume (20D)	1,440,627
Open	13.98
Previous Close	13.96
Day's Range	13.57 - 13.98
52-Week Range	10.57 - 33.33
Beta	1.49

About DNLI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DNLI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DNLI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Denali Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $0 misses estimates by $3.24M, with NaN% YoY growth.

EPS of -0.78 misses estimates by -0.07, with -14.71% YoY decline.

Why Price Moved

1 month ago

+11.8%

Denali Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

2 months ago

-8.21%

Denali Therapeutics shares are trading lower after Oppenheimer cut its price target on the stock from $50 to $42.

News

1 week ago · zacks.com

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?

1 week ago · zacks.com

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

1 month ago · zacks.com

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.

1 month ago · seekingalpha.com

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 sh...

1 month ago · zacks.com

Why You Shouldn't Bet Against Denali (DNLI) Stock

Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

2 months ago · zacks.com

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).